All In Biotech

Free tool

FAERS Monitor: Triumeq

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205551 or its brand name (Triumeq, Abacavir Sulfate, Dolutegravir Sodium, Lamivudine). Reports on generic versions are filed under their own applications.

Reports

6,334

Serious

3,413

54% of reports

Hospitalization

1,195

Death reported

329

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product dose omission issue827
  • pain809
  • anxiety757
  • emotional distress697
  • anhedonia628
  • chronic kidney disease473
  • fatigue336
  • depression315
  • renal failure309
  • nausea306
  • osteoporosis282
  • headache264
  • bone density decreased257
  • economic problem230
  • insomnia227

Reports by year received

View as table
YearReports
20111
20121
20131
20144
2015326
2016658
2017717
2018806
2019784
2020723
2021460
2022548
2023498
2024419
2025320
202668

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,825 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anhedoniaSignal62881.375.448,581
economic problemSignal23051.145.011,096
bone density decreasedSignal25727.524.36,481
osteoporosisSignal28222.920.45,860
chronic kidney diseaseSignal47320.819.18,870
emotional distressSignal69719.217.912,022
product dose omission issueSignal8279.48.86,238
anxietySignal7578.98.35,324
renal failureSignal3097.76.91,815
depressionSignal3154.64.1893
painSignal8094.44.12,165
insomniaSignal2272.82.5270
fatigue3361.41.345
headache2641.41.230
nausea3061.31.220

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.